We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BioVendor Group

BioVendor Group is an international group of biotechnology companies (BioVendor LM, BioVendor R&D, TestLine, ViennaLa... read more Featured Products: More products

Download Mobile App





BioVendor Presents Its Portfolio of IVD Products and Technologies for Lab Automation

By LabMedica International staff writers
Posted on 26 Apr 2022

BioVendor Group (Brno, Czech Republic) celebrated its 30th anniversary by presenting its key product portfolio, including CLIA, NGS, Microblot Array, microRNA and LAMP products, at ECCMID 2022. More...

In the NGS field, BioVendor showcased its new technology fastGEN for examination of the mutation status of oncomarkers in samples. The technology is based on ultra-deep sequencing of short amplicons obtained by a single polymerase chain reaction with special tagged hybrid primers. The company presented its user-friendly diagnostic kits with software solution for KRAS, NRAS, BRAF, EGFR and IDH 1/2 genes with excellent analytical parameters and fast processing. BioVendor demonstrated its GENOVESA software fastGEN module, a cloud all-in-one solution for the analysis of raw data (FASTQ files) with technical and application support.

Among its solutions for multiplex diagnostics, BioVendor presented Microblot-Array (MBA), a new generation of a market-unique immunoblot array in a microtiter plate format. MBA is designed for efficient multiplex diagnostics, enabling the simultaneous detection of multiple markers which is time and cost-saving. The technology eliminates the limited capacity of traditional BLOT strips and opens the way to high throughput testing. Simple processing can be done manually or automatically using any open ELISA analyzers. The comprehensive evaluation is ensured by the TestLine Reader and Software (SW) for complex image analysis, including results evaluation and connectivity to LIS. BioVendor also showcased its LAMP Assays for the direct detection of target nucleic acids without the need of the isolation step. The unique architecture of the LAMP method ensures its high sensitivity and specificity and a tolerance for inhibitory substances

BioVendor provided a virtual tour of its KleeYa automated CLIA analyzer that offers an attractive portfolio of innovative and established diagnostic parameters and provides a comprehensive chemiluminescence system for diagnostic laboratories. With a graphical user interface, users can learn to control the fully automated system in minutes. KleeYa software is designed to minimize the burden on laboratory staff. Thanks to augmented reality, technical support is available to users at any time, right in the lab with advise on operation, settings and minor service tasks.

Related Links:
BioVendor Group


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Myocardial Infarction Test
Finecare cTn I/NT-proBNP Rapid Quantitative Test
New
Vasculitis Diagnostic Test
AESKULISA Vasculitis-Screen
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: The new technology combines a rapid hemoglobin test with a smartphone app (Photo courtesy of 123RF)

Smartphone-Based Rapid Hemoglobin Test Accurately Detects Colorectal Cancer

Despite the availability of colorectal cancer screening programs, participation remains low, especially for fecal immunochemical tests (FIT), a non-invasive method to detect hidden blood in the stool.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.